Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.

Read entire article

Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.

Read entire article

Fortune Brands Innovations (FBIN) is under pressure from weak housing demand, shrinking profits, and leadership uncertainty. But while Wall Street hesitates, activist investor Ed Garden just made a massive $13.6 million insider purchase. Is this a value trap… or a smart-home turnaround hiding in plain sight?

Read entire article

Vital Farms stock has been absolutely scrambled by the 2026 egg glut, plunging more than 80% from its highs as profitability collapsed and short sellers flooded the farm. But coordinated insider buying, a debt-free balance sheet, and extreme institutional ownership suggest the setup may be far more explosive than the market currently realizes.

Read entire article

Nomad Foods may not be sexy, but Europe’s frozen-food empire is suddenly attracting serious insider buying, quant fund interest, and deep-value investors. With a near-7% dividend yield, aggressive buybacks, and a forward P/E near 5x, NOMD might be one of the market’s coldest contrarian opportunities.

Read entire article

Kraft Heinz (KHC) may no longer be just a sleepy dividend stock. After a nearly $5 million insider purchase by CEO Steven Cahillane, investors are revisiting the bull case: 6.6% yield, rising free cash flow, strong institutional ownership, and potential short-squeeze dynamics. Is Wall Street missing the turnaround?

Read entire article

LegalZoom (LZ) is becoming one of the most fascinating battleground stocks of 2026. With the CEO buying shares for the first time, institutions owning more than 100% of float, elevated short interest, and a debt-free balance sheet generating real free cash flow, bulls believe the legal-tech platform could be dramatically undervalued. Bears counter that AI could commoditize core services. At roughly 70% below all-time highs, the courtroom battle is officially underway. ⚖️🚀

Read entire article

Alexandria REIT (ARE) may be one of the market’s most fascinating contrarian plays. Founder Joel Marcus is aggressively buying shares while occupancy weakens, revenue shrinks, and Wall Street turns cautious. Here’s why this life-science REIT could either become a legendary recovery story… or a lab experiment gone wrong. 🧪🏢

Read entire article

S&P Global isn’t just a company—it’s the infrastructure of modern finance. With valuation down ~30% and insiders buying, is this a rare opportunity to own a wide-moat compounder at a discount?

Read entire article

GE HealthCare (GEHC) is quietly shaping up as a high-visibility MedTech play, combining insider buying, a $21.8B backlog, and AI-driven diagnostics. With valuation still reasonable and institutional ownership near record levels, this could be a compelling long-term compounder—if you’re patient on entry.

Read entire article